Astrocyte regulation of brain angiogenesis varies by disease and stage
Astrocytes’ dual role in brain angiogenesis
Astrocytes can help repair blood vessels after ischemic injury while contributing to pathological vessel formation in tumors such as glioblastoma. This review in Brain Research Bulletin summarizes mechanisms by which astrocytes regulate angiogenesis in central nervous system (CNS) diseases and outlines challenges for therapeutic research. It synthesizes existing knowledge rather than reporting new experimental findings.
Understanding astrocyte function requires considering both the disease and the stage following injury. The review examines how disease-specific signals—including hypoxia, tumor-derived factors, and amyloid-beta plaques—lead to different vascular responses. These differences are difficult to explain using approaches that uniformly promote or inhibit vessel formation.
Disease-associated subpopulations suggested by single-cell studies
Recent single-cell studies provide a basis for understanding astrocytes as disease-associated subpopulations rather than one uniform group. Moving beyond the traditional A1/A2 dichotomy, the review introduces a framework encompassing ischemia-associated, glioma-associated, and Alzheimer’s disease-associated astrocytes. However, the provided abstract alone does not allow verification of the cellular markers or classification criteria for each group.
The main mechanisms discussed include the vascular endothelial growth factor (VEGF) and angiopoietin (Ang) axes, HMGB1 signaling, and the sonic hedgehog (Shh) pathway. The review also considers the transfer of microRNAs (miRNAs) carried by exosomes. The abstract does not provide evidence to map these pathways one-to-one onto disease-associated subpopulations or to conclude that a specific pathway determines vascular structure and function.
A key challenge highlighted by the review is the time-dependent action of VEGF. VEGF may be harmful during the acute phase but beneficial for vascular repair during recovery. This raises a research question about distinguishing stages following injury when evaluating treatment strategies. The abstract presents no results validating specific times for activating or inhibiting VEGF in patients with stroke or tumors.
Potential of astrocyte-targeted therapies and remaining challenges
In ischemic injury, promoting angiogenesis that supports repair is one therapeutic research goal; in glioblastoma, inhibiting pathological angiogenesis is another. The expected effects of targeting the same cells or signals may differ by disease and stage.
Astrocyte-specific gene editing and engineered exosomes are proposed as future research directions in the review. It is too early to regard them as validated treatments. The provided material is limited to the abstract and bibliographic information; experimental conditions, effect sizes, safety, and efficacy in patients in the individual studies could not be verified. Clinical applications should be treated as prospects requiring further validation.
Source: Review abstract and bibliographic information indexed in Europe PMC.
Research Summary (Reference Context)
Astrocytes exhibit a context-dependent duality in CNS angiogenesis, promoting repair in ischemia while driving pathology in tumors. Emerging single-cell studies have identified disease-associated astrocyte subsets that utilize distinct pathways like VEGF/Ang, HMGB1, and exosomal miRNA. A key challenge is the temporal dichotomy of VEGF action, transitioning from acutely detrimental to beneficial during recovery. Future therapies, such as astrocyte-specific gene editing and engineered exosomes, aim to provide context-specific CNS treatments.
The practical implication of this review is that research on astrocyte-targeted vascular regulation should account for both disease and the stage following injury. For example, when assessing strategies to support vascular repair after ischemic injury, researchers should distinguish effects during the acute phase from those during recovery. In glioblastoma research, suppressing pathological angiogenesis is a separate objective. These distinctions provide a reason to set different evaluation conditions and expected effects even when the same signal is being modulated. The review abstract, however, does not specify administration timing or present efficacy in patients. Gene editing and engineered exosomes are also proposals for future research; they should not be interpreted as clinical evidence supporting treatment decisions.